Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
作者信息
Schindléry C
出版信息
Med J Aust. 1988 Jun 20;148(12):662-3. doi: 10.5694/j.1326-5377.1988.tb116355.x.
Abstract
摘要
相似文献
1
Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.重型β地中海贫血患者中由去铁胺导致的听力损失。
Med J Aust. 1988 Jun 20;148(12):662-3. doi: 10.5694/j.1326-5377.1988.tb116355.x.
2
Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
Med J Aust. 1987 Aug 17;147(4):177-9. doi: 10.5694/j.1326-5377.1987.tb133351.x.
3
Hearing loss and desferrioxamine in homozygous beta-thalassemia.纯合子β地中海贫血中的听力损失与去铁胺
Audiology. 1988;27(4):207-14. doi: 10.3109/00206098809081591.
4
Hearing impairment during deferoxamine therapy for thalassemia major.重型地中海贫血去铁胺治疗期间的听力损害。
J Pediatr. 1991 May;118(5):826-7. doi: 10.1016/s0022-3476(05)80063-0.
5
Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
Br J Haematol. 1989 Nov;73(3):403-9. doi: 10.1111/j.1365-2141.1989.tb07761.x.
6
[Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
Pediatr Med Chir. 1988 Sep-Oct;10(5):503-4.
7
[Evaluation of auditory function in homozygous beta-thalassemia].[纯合子β地中海贫血听觉功能评估]
Pediatr Med Chir. 1986 Sep-Oct;8(5):703-5.
8
Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.长期大剂量皮下注射去铁胺疗法的眼毒性和耳毒性
Can J Ophthalmol. 1985 Jun;20(4):153-6.
9
Can deferoxamine be considered an ototoxic drug?
Scand Audiol Suppl. 1988;30:237-8.
10
Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.长期去铁胺（DFO）治疗下纯合子β地中海贫血的神经生理学和神经耳科学研究
Acta Neurol Scand. 1991 May;83(5):306-8. doi: 10.1111/j.1600-0404.1991.tb04707.x.
Zotero 插件